



Supplementary Material

Article Title: Efficacy for Psychopathology and Body Weight and Safety of Topiramate Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials

Authors: Christoph U. Correll, MD^a; Lawrence Maayan, MD; John Kane, MD; Marc De Hert, MD, PhD; and Dan Cohen, MD, PhD

DOI Number: 10.4088/JCP.15r10373


List of Supplementary Material for the article

1. [eFigure 1](#) Standardized Mean Difference in Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) Total Score (Change or Endpoint) By Clozapine vs. Non-Clozapine Antipsychotic Treatment
2. [eFigure 2](#) Weighted Mean Difference in Body Weight (Change or Endpoint) By Clozapine vs. Non-Clozapine Antipsychotic Treatment

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eFigure 1. Standardized Mean Difference in Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) Total Score (Change or Endpoint) By Clozapine vs. Non-Clozapine Antipsychotic Treatment



Supplementary eFigure 2. Weighted Mean Difference in Body Weight (Change or Endpoint) By Clozapine vs. Non-Clozapine Antipsychotic Treatment

